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ABSTRACT
Objectives To study the effects of metformin on the
incidence of vitamin B-12 deficiency (<150 pmol/l), low
concentrations of vitamin B-12 (150-220 pmol/l), and
folate and homocysteine concentrations in patients with
type 2 diabetes receiving treatment with insulin.
Design Multicentre randomised placebo controlled trial.
Setting Outpatient clinics of three non-academic
hospitals in the Netherlands.
Participants 390 patients with type 2 diabetes receiving
treatment with insulin.
Intervention 850 mg metformin or placebo three times a
day for 4.3 years.
MainoutcomemeasuresPercentagechangein vitaminB-
12, folate, and homocysteine concentrations from
baseline at4, 17, 30, 43, and 52 months.
Results Compared with placebo, metformin treatment
was associated with a mean decrease in vitamin B-12
concentrationof −19%(95%confidenceinterval −24%to
−14%; P<0.001) and in folate concentration of −5% (95%
CI −10% to −0.4%; P=0.033), and an increase in
homocysteine concentration of 5% (95% CI −1% to 11%;
P=0.091). After adjustment for body mass index and
smoking, no significant effect of metformin on folate
concentrations was found. The absolute risk of vitamin
B-12 deficiency (<150 pmol/l) at study end was 7.2
percentage points higher in the metformin group than in
the placebo group (95% CI 2.3 to 12.1; P=0.004), with a
number needed to harm of 13.8 per 4.3 years (95% CI
43.5 to 8.3). The absolute risk of low vitamin B-12
concentration (150-220 pmol/l) at study end was 11.2
percentage points higher in the metformin group (95% CI
4.6 to 17.9; P=0.001), with a number needed to harm of
8.9 per 4.3 years (95% CI 21.7 to 5.6). Patients with
vitamin B-12 deficiency at study end had a mean
homocysteine level of 23.7 µmol/l (95% CI 18.8 to 30.0
µmol/l), compared with a mean homocysteine level of
18.1 µmol/l (95% CI 16.7 to 19.6 µmol/l; P=0.003) for
patients with a low vitamin B-12 concentration and 14.9
µmol/l (95% CI 14.3 to 15.5 µmol/l; P<0.001 compared
withvitaminB-12deficiency;P=0.005comparedwithlow
vitamin B-12) for patients with a normal vitamin B-12
concentration (>220 pmol/l).
Conclusions Long term treatment with metformin
increases the risk of vitamin B-12 deficiency, which
results in raised homocysteine concentrations. Vitamin
B-12 deficiency is preventable; therefore, our findings
suggest that regular measurement of vitamin B-12
concentrations during long term metformin treatment
should be strongly considered.
Trial registration Clinicaltrials.gov NCT00375388.
INTRODUCTION
Metformin is considered a cornerstone in the treat-
ment of diabetes and is the most frequently prescribed
first line therapy for individuals with type 2 diabetes.
1
In addition, it is one of a few antihyperglycaemic
agents associated with improvements in cardio-
vascular morbidity and mortality,
23 which is a major
cause of death in patients with type 2 diabetes.
4
Therearefewdisadvantagestotheuseofmetformin.
Metformindoes,however,inducevitaminB-12malab-
sorption, which may increase the risk of developing
vitamin B-12 deficiency
5-7—a clinically important and
treatable condition. In addition, metformin treatment
has been reported to be associated with decreased
folate concentration, although the mechanism of this
effect has not been elucidated.
8 Finally, decreases in
both folate and vitamin B-12 concentrations might, in
turn, result in an increase in homocysteine concentra-
tions (web figure A), an independent risk factor for
cardiovascular disease, especially among individuals
with type 2 diabetes.
9-11
All current evidence on vitamin B-12 deficiency in
metformin treatment comes from short term
studies.
5-712-14 No long term, placebo controlled data
on the effects of metformin on concentrations of vita-
min B-12 in patients with type 2 diabetes have been
reported. In addition, placebo controlled data on the
effects of metformin on homocysteine concentrations
intype2diabetesaresparse,
1215andagainnolongterm
data are available.
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serum concentrations of vitamin B-12, folate, and
homocysteine in patients with type 2 diabetes in a
long term placebo controlled trial.
METHODS
Patients
ThisstudywaspartoftheHyperinsulinaemia:theOut-
come of its Metabolic Effects (HOME) randomised
trial investigating the effects of metformin on meta-
bolism and on microvascular and macrovascular dis-
ease in type 2 diabetes. The trial included 390 patients
aged30-80yearswithtype2diabeteswhowerereceiv-
ing treatment with insulin, as previously described.
316
Study design
The HOME trial was conducted in the outpatient
clinics of three non-academic hospitals in the Nether-
lands: Bethesda General Hospital, Hoogeveen;
Diaconessen Hospital, Meppel; and Aleida Kramer
Hospital, Coevorden. Patients were randomly
assigned by a computer program to receive either
850 mg of metformin three times a day or 850 mg of
placebo thrice daily, which were provided in identical
looking boxes.
The trial consisted of three phases: the 12 week
pre-randomisation phase, in which patients were trea-
ted with insulin only and concomitant medication was
discontinued; the 16 week short term treatment phase,
at the beginning of which patients were randomised to
receive either metformin or placebo in addition to
insulin therapy; and the four year (48 month) long
term treatment phase (fig 1). An interim analysis was
conductedattheendoftheshorttermtreatmentphase,
duringwhichthetreatmentcodeswerenotdisclosedto
the investigators.
31216
Visits and data collection
Patients visited the clinics at the start of the pre-rando-
misationphase(threemonthsbeforerandomisation),at
baseline (for randomisation to metformin or placebo),
and one month after baseline (to check the tolerance of
the drug titration), then subsequently every three
months until the end of the trial. During these visits, a
physicalexaminationwascarriedout,amedicalhistory
was taken, and laboratory investigations were per-
formed.Atbaseline,andafter10and52months,dietary
counselling was given to all patients.
Laboratory investigations
Blood samples for this study were drawn at baseline
and after 4, 17, 30, 43, and 52 months, and stored at
−80°C until analysis. Concentrations of vitamin B-12,
folate, and homocysteine were measured in serum.
Vitamin B-12 and folate concentrations were deter-
minedbyanelectrochemiluminescenceimmunoassay
(ECLIA) using the competition principle. The mean
intra-assay coefficients of variation for vitamin B-12
and folate were 2.3% and 3.5%, respectively. The
mean inter-assay coefficients were 2.9% and 4.7%,
respectively.
Total homocysteine concentration was measured
using a kit from Chromsystems (Martinsried, Ger-
many). The results were corrected against two types
of “consensus plasma samples” (SKML, Nijmegen,
the Netherlands) that had concentrations of 13 µmol/
l and 55 µmol/l. The correction factor found was 0.90.
Theintra-assaycoefficientsofvariationwere2.2%and
1.8%at12.8µmol/land72.2µmol/l,respectively.The
inter-assay coefficients of variation were 6.1% and
5.2% at 9.8 µmol/l and 21.1 µmol/l, respectively.
In the HOME trial, vitamin B-12, folate, and homo-
cysteineconcentrationshadbeenmeasuredpreviously
in samples obtained at baseline and after 16 weeks of
treatment.
12 To investigate the stability of the assay
procedures, we compared the previously obtained
values with values obtained for the present investiga-
tion. The correlation between old and new measure-
ments of vitamin B-12 was 0.58 for baseline
measurements and 0.91 for measurements taken after
16 weeks; for folate these values were 0.90 and 0.83,
respectively, and for homocysteine 0.99 and 0.99,
respectively.Therelativelylowcorrelationforvitamin
B-12 values obtained at baseline was caused by five
cases for which a large discrepancy existed between
old and new values; these cases were subsequently
excluded from analyses involving vitamin B-12.
Statistical analysis
Sample size calculations were based on expected dif-
ferences in the occurrence of disease related end
points, as described previously.
3 With the sample size
obtained,however,adecreaseinvitaminB-12concen-
tration of 5% in the metformin group compared with
the placebo group according ANCOVA tests should
be detectable at a two sided 95% confidence level,
with a power of 0.82.
We log transformed data on vitamin B-12, folate,
and homocysteine concentrations before analysis
because their distribution was skewed. Data are given
as geometric means with 95% confidence intervals.
Given that log values are not directly interpretable,
the antilogs are reported instead. These values are the
geometric mean percentage change from baseline.
The end point of interest was the percentage change
of each variable from baseline at 4, 17, 30, 43, and
52 months, which was calculated from baseline values
and the summary mean. The differences between the
metforminandtheplacebogroupweretestedbyacen-
tralttestonlogtransformedvalues.Wealsocalculated
Pre-randomisation
12 weeks
13 2
Enrolment
Insulin treatment
Short term treatment phase
16 weeks
Long term treatment phase
4 years
Tablets of placebo or metformin
Randomisation Interim analysis
Fig 1 | HOME trial schedule
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ciency,whichwasdefinedasavitaminB-12concentra-
tion below the value of 150 pmol/l, and of having low
vitamin B-12 levels, which was defined as a vitamin B-
12 concentration below 220 pmol/l but above 150
pmol/l.
17 All analyses were by intention to treat and
used the last observation carried forward. To test
whether results obtained were robust, we also used
mixedmodelsanalysistoimputemissingdata.Patients
with vitamin B-12 concentrations below 150 pmol/l at
baseline, at the interim analysis, or at both time points
were supplemented at 16 weeks (n=8) and, therefore,
excluded from analyses after 16 weeks.
We used linear mixed models to explore the effects
ofmetforminonconcentrationsofvitaminB-12,folate,
and homocysteine. We also investigated whether met-
forminassociatedchangesinhomocysteineconcentra-
tions, if any, could be explained by changes in the
concentrations of folate, vitamin B-12, or both, and, if
so, whetherthe changeswere independent ofage,gen-
der, duration of diabetes, smoking, body mass index,
insulin dose, serum creatinine, high density lipopro-
tein cholesterol, or glycated haemoglobin. The good-
ness of fit between alternative models was compared
using the maximum likelihood technique.
RESULTS
Patients
We screened the medical files of all three participating
outpatient clinics and identified 745 eligible patients.
All were approached to enrol into the trial and 390
individuals gave written informed consent. A total of
196 patients were randomised to receive metformin
and 194 to receive placebo. Out of the 390 included
patients,277individuals(72%)werestillreceivingmet-
forminorplaceboattheendofthetrial(fig2).Atotalof
46 patients (30 metformin, 16 placebo) discontinued
because of adverse effects, which have been described
more extensively elsewhere.
3 Only two participants
were lost to follow-up (at 33 and 26 months, respec-
tively), both of whom were in the metformin group.
The actual mean dose in the metformin group was
2050 mg a day. At the final visit, laboratory samples
were available for 256 patients (127 metformin, 129
placebo). The main outcomes of this trial have been
reported previously.
3
Table 1showsbaselinecharacteristics of allpatients
analysed. Five randomised patients were excluded
fromtheanalysisbecauseofpoorcorrelationsbetween
old and newly measured vitamin B-12 values (see
Methods). Patients randomised to metformin were
older than those randomised to placebo (64±10 years
v 59±11 years), and were more likely to have a history
ofcardiovasculardiseaseandlesslikelytobeasmoker
(30 (19%) v 59 (30%)). The other characteristics were
comparable between the two treatment groups.
Vitamin B-12, folate, and homocysteine concentrations
Duringthe52monthsofplacebotreatment,vitaminB-
12concentrationincreasedfrombaselineby0.2pmol/
l (0% change, 95% confidence interval −3% to 4%),
folate increased by 1.01 nmol/l (8%, 95% CI 4% to
12%), and homocysteine increased by 1.60 μmol/l
(20%, 95% CI 16% to 25%; fig 3). During metformin
treatment, vitamin B-12 decreased by 89.8 pmol/l
(−19%,95%CI−22%to−15%)frombaseline,whereas
folate concentration increased by 0.21 nmol/l (3%,
95% CI −1% to 6%) and homocysteine concentration
increased by 3.26 μmol/l (26%, 95% CI 21% to 31%).
Compared with placebo, metformin treatment was
associated with a 19% decrease in vitamin B-12 con-
centration (95% CI −24% to −14%; P<0.001) and a
5% decrease in folate concentration (95% CI −10% to
−0.4%; P=0.033), and a 5% increase in homocysteine
concentrations (95% CI −1% to 11%; P=0.091). The
effects of metformin on concentrations of vitamin B-
12, folate, and homocysteine were re-analysed follow-
ing adjustment for age, previousmetformin treatment,
duration of diabetes, gender, insulin dose, and smok-
ing habits. None of these variables materially changed
the results for vitamin B-12 and homocysteine (data
not shown), but they did have an effect on the results
for folate. After adjustment for body mass index and
smoking, no significant effect of metformin on folate
concentration was found (change in concentration
compared with placebo −0.1%; P=0.57).
At baseline, three patients (1.6%) in the metformin
group and four (2.2%) in the placebo group had vita-
min B-12 deficiency (vitamin B-12 concentration
<150 pmol/l), whereas 14 patients (7.3%) and 14
patients (7.5%), respectively, had a low vitamin B-12
concentration (150-220 pmol/l). At the end of the
study period, 19 patients (9.9%) in the metformin
group and five (2.7%) in the placebo group had vita-
min B-12 deficiency, whereas 35 patients (18.2%) and
13 patients (7.0%), respectively, had a low vitamin
B-12 concentration.
TheriskforvitaminB-12deficiencyatstudyendwas
7.2 percentage points higher in the metformin group
Placebo (n=194) Metformin (n=196)
Metformin (n=131)
Eligible patients (n=745)
Patients enrolled and randomised (n=390)
Excluded (n=355)
Did not give informed consent
Non-completers (n=65):
  Adverse events (n=30)
  Contraindications (n=2)
     Renal failure (n=0)
     Heart failure (n=1)
     Liver failure (n=1)
  Fatal disease related end point (n=9)
  Withdrawal of consent (n=22)
  Lost to follow-up (n=2)
Placebo (n=146)
Non-completers (n=48):
  Adverse events (n=16)
  Contraindications (n=1)
     Renal failure (n=0)
     Heart failure (n=1)
     Liver failure (n=0)
  Fatal disease related end point (n=6)
  Withdrawal of consent (n=25)
  Lost to follow-up (n=0)
Fig 2 | HOME patient profile
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P=0.004),withanumberneededtoharmof13.8per4.
3 years (95% CI 43.5 to 8.3). The risk difference at
study end for a low vitamin B-12 concentration was
11.2 percentage points higher in the metformin group
(95% CI 4.6 to 17.9; P=0.001), with a number needed
to harm of 8.9 per 4.3 years (95% CI 21.7 to 5.6). The
hazard ratio for developing vitamin B-12 deficiency
when treated with metformin was 5.5 (95% CI 1.6 to
19.1;P=0.01),andthehazardratioforalowvitaminB-
12 concentration was3.0 (95% CI1.3 to 6.6; P=0.007).
Patients with a vitamin B-12 deficiency at the end of
the study had a mean homocysteine level at study end
of23.7µmol/l(95%CI18.8to30.0µmol/l),compared
with 18.1 µmol/l (95% CI 16.7 to 19.6 µmol/l;
P=0.003) for patients with a low vitamin B-12 concen-
tration and 14.9 µmol/l (95% CI 14.3 to 15.5 µmol/l;
P<0.001 compared with vitamin B-12 deficiency;
P=0.005 compared with low vitamin B-12) for patients
with a normal vitamin B-12 level (>220 pmol/l; fig 4).
Homocysteine concentrations did not differ signifi-
cantly between treatment groups when stratified for
end of treatment vitamin B-12 concentration.
Linear mixed model
The interaction between treatment and time was a sig-
nificant determinant of vitamin B-12 concentration
(P=0.023)—that is, the lowering effect of metformin
on vitamin B-12 concentrations increased with time.
Body mass index and smoking were strong inverse
determinants of folate concentration (P=0.003 and
P<0.0001, respectively). There was no relation
between time and folate concentration. After adjust-
ment for body mass index and smoking, treatment
with metformin was not a significant determinant of
folate concentration, nor was the interaction between
treatment and time (P=0.57 and P=0.23, respectively).
Vitamin B-12 and folate levels were strong determi-
nants of homocysteine concentration (P<0.0001).
Homocysteine concentration increased with age at
baseline (P<0.0001). There was no significant inter-
action between treatment and time for homocysteine
concentrations (P=0.16).
Additional analysis
Perprotocolanalysisusingonlyavailabledataforthose
patients who remained in the trial until the final visit
(n=256) yieldedsimilar resultstoouroriginalintention
to treat analysis (data not shown). General mixed
model analysis yielded similar results to analysis using
last observation carried forward (data not shown).
DISCUSSION
Our study on the long term effects of metformin treat-
ment on serum concentrations of vitamin B-12, folate,
andhomocysteineinpatientswith type2diabetestrea-
ted with insulin had three main findings. Firstly, met-
formin significantly reduced concentrations of vitamin
B-12, in accordance with findings from previous
studies.
131819 Importantly, our study shows that this
decrease is not a transitory phenomenon, but persists
and grows over time. Secondly, a small, significant
decrease infolate concentrations was found inthe met-
formin group compared with the placebo group; how-
ever,thisreductionwasnotstatisticallysignificantafter
adjustments for body mass index and smoking.
Thirdly, the decrease in vitamin B-12 concentrations
wasassociatedwithanincreaseinhomocysteinelevels,
whichwasnotstatisticallysignificant.Furtheranalyses,
however, showed that homocysteine concentrations
didincreaseinindividualsinwhomvitaminB-12levels
decreased below the concentration generally consid-
eredtoindicateclinicaldeficiency—thatis,150pmol/l.
The finding of decreases in vitamin B-12 concentra-
tion during metformin treatment is not novel and has
been reported before. A novel finding here, however,
is that the decrease in vitamin B-12 levels is progres-
sive. Furthermore, concentrations in some patients
drop to the level at which most authorities agree vita-
min substitution is required. This is also a novel find-
ing, because although earlier trials in well fed, middle
aged patients showed that metformin decreases vita-
min B-12 concentrations, levels recorded remained
within the normal range.
5614
Table 1 |Baseline characteristics of all patients analysed
Metformin (n=194) Placebo (n=191)
Demographics
Men:women (n:n) 81:113 95:96
Age (years) 64 (10) 59 (11)
Currently smoking (n (%)) 30 (19) 59 (30)
Duration of diabetes (years) 14 (9) 12 (8)
Insulin treatment (years) 7 (8) 6 (6)
Concomitant medication
Lipid lowering drugs (n (%)) 32 (17) 29 (15)
Blood pressure lowering drugs (n (%)) 91(47) 74 (39)
Metabolic variables
Weight (kg) 85(16) 87 (15)
Body mass index (kg/m
2) 30 (5) 30 (5)
Waist to hip ratio
Men 1.02 1.02
Women 0.93 0.92
Plasma glycated haemoglobin (HbA1c) 7.9 (1.2) 7.9 (1.2)
Daily dose of insulin (IU/day) 61 64
Systolic blood pressure (mm Hg) 160 (25) 160 (25)
Diastolic blood pressure (mm Hg) 86 (12) 86 (11)
Total cholesterol (mmol/l) 5.6 (1.3) 5.5 (1.2)
Low density lipoprotein cholesterol (mmol/l) 3.6 (1.1) 3.4 (1.0)
Triglycerides (mmol/l) 1.7 (1.2) 1.9 (1.5)
High density lipoprotein cholesterol (mmol/l) 1.3 (0.4) 1.3 (0.4)
Vitamin B-12 (pmol/l) 378 (130) 380 (135)
Folate (nmol/l) 18.7 (7.2) 18.7 (7.5)
Homocysteine (µmol/l) 14.4 (9.7) 14.6 (10.3)
Previous cardiovascular disease
Myocardial infarction (n (%)) 24 (12) 21 (11)
Cardiovascular intervention (n (%)) 27 (14) 17 (9)
Stroke (n (%)) 8 (4) 8 (4)
Non-traumatic amputation (n (%)) 5 (3) 3 (2)
Values are mean (standard deviation) unless otherwise stated.
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vitamin B-12 and intrinsic factor in the ileum, an effect
that can be reversed by increasing calcium intake.
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The consequences of clinically important decreases in
vitamin B-12 concentrations—such as macrocytic
anaemia, neuropathy, and mental changes—can be
profound. We note that there is no consensus on the
issue of whether “asymptomatic” vitamin B-12 defi-
ciency should be treated.
20 However, studies show
thatsomesymptomsofvitaminB-12deficiencyaredif-
ficulttodiagnoseandcanbeirreversible,andtreatment
of vitamin B-12 deficiency is relatively easy, cheap,
safe, and effective,
21-24 in effect arguing in favour of
treatment. In addition, although the necessity of treat-
ing “spontaneous” vitamin B-12 deficiency may be
debated, one should be more easily inclined to treat
drug induced vitamin B-12 deficiency, as a key princi-
ple of drug prescription is to do no harm. On the other
hand, our study shows that it is reasonable to assume
harm will eventually occur in some patients with met-
formin induced low concentrations of vitamin B-12.
Folate concentration increased in both the metfor-
min group and the placebo group, possibly as a result
ofdietarycounsellingreceivedbyallpatientsthrough-
out the trial. Our short term interim analysis showed a
significantly larger increase in folate concentration in
the placebo group,
12 a finding that was initially repli-
cated in the current analysis but that disappeared after
adjustment for body mass index and smoking.
Previous studies have shown either no or small
effects of metformin treatment on concentrations of
homocysteine.
13142526 We clearly show that homocys-
teineconcentrationsdoincreasewithdecreasinglevels
of vitamin B-12 (fig 4). The finding that metformin
treatment significantly lowered concentrations of vita-
minB-12 butdidnotsignificantlyalterlevels ofhomo-
cysteine probably reflects the relatively low incidence
of vitamin B-12 deficiency in the entire study popula-
tion.Astreatmentwithmetformincontinues,however,
we expect that vitamin B-12 levels will continue to
decrease, making increases in homocysteine concen-
trations inevitable in time.
Strengths and limitations of study
Strengths of our study include the randomised, pla-
cebo controlled, double blind design and its relatively
long follow-up of 4.3 years, as well as frequent serum
collection. Furthermore, the study was conducted in a
non-academic setting and, therefore, the findings have
high value in a community setting.
Anotherstrengthisthatweusedlastobservationcar-
riedforwardinthisanalysisbecausethismethodiscon-
sidered more conservative than general mixed model
analysis, “freezing” any observed divergence between
twogroupsbyretainingthelastobservationmade.Ina
mixedmodelanalysiswithmissingdata,estimationsof
future observations are made on the basis of observa-
tions made earlier in the trial, thereby reflecting a
divergence more accurately but less conservatively.
Limitationsofourstudyincludethefactthatwemea-
sured only total vitamin B-12 levels and not levels of
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Fig 3 | Concentrations of vitamin B-12, folate, and
homocysteine with 95% confidence intervals. Solid lines
represent the metformin group, dotted lines the placebo
group. Number of available samples for the metformin and
placebo group is indicated. Five patients were excluded from
the analysis because of poor correlations between old and
newly measured vitamin B-12 values (see Methods). In
addition, some patients had vitamin B-12 levels below 150
pmol/l at baseline, at interim analysis, or at both stages, and
were supplemented; these individuals were also excluded.
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may have been more precise indicators of vitamin
B-12 status. Finally, it is likely that, if anything, we
underestimated the impact of metformin treatment on
theriskofclinicallyimportantvitaminB-12deficiency.
We showed that metformin treatment was associated
not only with a raised risk of developing vitamin B-12
concentrations below 150 pmol/l but also with an ele-
vated risk of developing vitamin B-12 levels between
150 and 220 pmol/l, which is likely to represent clini-
callyimportantvitaminB-12deficiencyinatleastsome
individuals.
27Afurtherreasonthatwemayhavesome-
what underestimated the adverse effects of metformin
isthatallparticipantsinourtrialreceivedfrequentdiet-
arycounselling,whichmayhaveattenuatedtheimpact
of metformin treatment on vitamin status and may not
be available in routine clinical practice.
Conclusions and policy implications
In conclusion, we showed that in patients with type 2
diabetes being treated with insulin, those additionally
treated with metformin had a seven percentage point
greater absolute risk of vitamin B-12 deficiency than
those treated with placebo during 4.3 years of follow-
up. In addition, the reduction in vitamin B-12 concen-
tration associatedwith metforminincreased withtime.
Current guidelines indicate that metformin is a cor-
nerstone in the treatment of type 2 diabetes, but make
no recommendations on the detection and prevention
of vitamin B-12 deficiency during treatment. Our data
provide a strongcase forroutine assessmentofvitamin
B-12levelsduringlongtermtreatmentwithmetformin.
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